关于蓝星安迪苏股份有限公司 向特定对象发行 A 股股票申请文件的 审核问询函的回复报告 保荐人（主承销商） 上海证券交易所： 根据贵所于 2025 年 4 月 29 日出具的《关于蓝星安迪苏股份有限公司向特定 对象发行股票申请文件的审核问询函》（上证上审（再融资）〔2025〕131 号） （以下简称"审核问询函"）的要求，蓝星安迪苏股份有限公司（以下简称"安 迪苏"、"发行人"或"公司"）已会同中信证券股份有限公司（以下简称"保 荐机构"或"保荐人"）、毕马威华振会计师事务所（特殊普通合伙）（以下简 称 "申报会计师"或"毕马威"）、北京市金杜律师事务所（以下简称"发行 人律师"、"申报律师"或"金杜"）等有关中介机构，本着勤勉尽责、诚实守 信的原则，对审核问询函所列的问题进行了逐项核查和落实，现回复如下，请予 审核。 本审核问询函回复报告的字体代表以下含义： | 审核问询函所列问题 | 黑体 | | --- | --- | | 对问题的回复 | 宋体 | | 申报文件的修订、补充披露（如有） | 楷体（加粗） | 如无特别说明，本审核问询函回复报告中的简称或名词的释义与《蓝星安迪 苏股份有限公司向特定对象发 ...

证券代码：600299 证券简称：安迪苏 公告编号：2025- 033 特此公告。 蓝星安迪苏股份有限公司董事会 2025 年 7 月 16 日 附件：丁冰晶先生简历 蓝星安迪苏股份有限公司 关于聘任公司副总经理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为完善蓝星安迪苏股份有限公司（以下简称"公司"）治理结构，保证公 司管理层工作的规范运作，根据《公司法》《公司章程》及相关法律法规的规 定，公司董事会提名委员会提名并审核副总经理候选人的任职资格，发表审核 意见如下：经审核丁冰晶先生的个人履历(简历后附)及资料，其具备担任公司 高级管理人员的任职资格和履职能力，不存在《公司法》《公司章程》中规定 不得担任公司高级管理人员的情形；不存在被中国证监会采取市场禁入措施， 并且禁入期限尚未届满的情形；不存在被证券交易所公开认定为不适合担任上 市公司高级管理人员，且期限未满的情形；也未曾受到中国证监会和证券交易 所的处罚或惩戒。因此，同意将聘任丁冰晶先生为公司副总经理的议案提交董 事会审议。 公司于 2025 年 7 月 1 ...

Core Insights - The baking enzyme preparation industry in China is experiencing rapid growth driven by the expanding market for baked goods and increasing consumer demand for healthy, functional products, particularly low-sugar and high-fiber options [1][14] - The market size of China's baking enzyme preparation industry is projected to reach approximately 2.15 billion yuan in 2024, with a year-on-year growth of 15%, and is expected to further grow to 2.48 billion yuan by 2025 [14] - The industry is characterized by a complete supply chain, including upstream raw material supply, midstream production, and downstream applications, with significant advancements in technology and product innovation [6][12] Industry Overview - Baking enzyme preparations are natural protein catalysts extracted through biotechnology, aimed at improving the quality, processing performance, and nutritional value of baked goods [2][3] - These enzymes enhance dough extensibility, fermentation efficiency, delay aging, and optimize texture by breaking down components such as starch, protein, or cellulose [2][3] - The main types of baking enzymes include amylases, proteases, xylanases, lipases, and glucose oxidases, sourced from microorganisms or plants, known for their efficiency and safety [2][3] Market Dynamics - The retail market for baked goods in China is expected to reach 611.07 billion yuan in 2024, growing at a rate of 8.8%, with health-oriented and scenario-based products becoming new consumer hotspots [8] - The number of baking stores in China is projected to increase from 285,000 in 2020 to 338,000 by 2025, although the annual growth rate has slowed from 5.6% to 0.6% [10] - The enzyme preparation industry is expected to produce 2.074 million tons in 2024, reflecting a year-on-year growth of 7.5%, with food industry applications maintaining a 42.3% market share [12][14] Competitive Landscape - The baking enzyme preparation industry in China is characterized by a competitive landscape where international giants dominate the high-end market, while domestic companies are rapidly catching up [18][20] - Major international brands like Novozymes and Genencor lead the high-end market, while domestic firms such as Yidoli and Blue Biological are making strides in basic enzyme products and gradually moving into high-end fields [18][20] - The market concentration is increasing, with the East China region accounting for over 60% of the market share, driven by technological advancements and economies of scale [18][20] Development Trends - The industry is evolving towards high-end technology, health sustainability, and global market integration, with innovations in biotechnology driving the development of efficient and stable enzyme preparations [23][24] - There is a growing demand for functional enzyme preparations that cater to health-conscious consumers, with a shift towards low-sensitivity and high-fiber products [24] - The domestic market is expanding, particularly in the eastern regions, while companies are also establishing production facilities in Southeast Asia to leverage local resources and reduce costs [25]

Group 1 - The company announced the resignation of Vice President Frank Chmitelin, effective from July 1, 2025, due to retirement [1][2]. - Frank Chmitelin has completed the necessary work handover according to relevant laws and company regulations, ensuring that his departure will not affect the company's normal operations and management [2][3]. - The company expressed gratitude for Frank Chmitelin's contributions to its development and compliance during his tenure as Vice President [3].

| 姓名 | 离任 职务 | 离任时间 | | 原定任期 到期日 原因 | 离任 | 是否继续在 上市公司及 其控股子公 | 具体 职务 （如 | 是否存在未 履行完毕的 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | | 公开承诺 | | | | | | | | 司任职 | 适用） | | | Frank | 副总 | 年 2025 7 | 2027 | 年 退休 9 | | 否 | 不适 | 否 | | Chmitelin | 经理 | 月 日 1 | 月 | 日 18 | | | 用 | | 蓝星安迪苏股份有限公司 关于高级管理人员离任的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 蓝星安迪苏股份有限公司（以下简称"公司"）董事会于近日收到公司副总经 理 Frank Chmitelin 先生的书面辞职报告。 一、离任的基本情况 证券代码：600299 证券简称：安迪苏 公告编号：2025-032 二、离任对公司的影 ...

Group 1 - The company received an inquiry letter from the Shanghai Stock Exchange regarding its application for a specific issuance of A-shares [1][2] - The company, along with relevant intermediaries, conducted a thorough study and provided detailed responses to the questions raised in the inquiry letter [1] - The issuance of A-shares is subject to approval from the Shanghai Stock Exchange and registration consent from the China Securities Regulatory Commission, with uncertainty regarding the approval timeline [2] Group 2 - The company will fulfill its information disclosure obligations in accordance with relevant laws and regulations as the process progresses [2]

Core Viewpoint - Blue Star Adisseo Co., Ltd. is seeking to raise funds through a specific stock issuance, with a total investment of 6.857 billion yuan for four projects and working capital, aiming for an internal rate of return between 13.57% and 25% [2][3]. Fundraising and Investment Projects - The total investment for the fundraising projects is 6.857 billion yuan, with a maximum of 3 billion yuan to be raised, allocated to four projects and 900 million yuan for working capital [2]. - The construction period for the four projects ranges from 15 to 26 months, with expected benefits from cost reductions and additional income from biogas [2]. Project Details - The first project is a solid methionine production project with an investment of approximately 493.23 million yuan, accounting for 100% of the total investment for this project [3][4]. - The second project involves a special feed additive with a total investment of 304.97 million yuan, with 60 million yuan sourced from the fundraising [11]. - The third project focuses on acrylic wastewater treatment and water reuse, with a total investment of 324.97 million yuan and 100 million yuan from the fundraising [15][19]. Cost Estimation and Reasonableness - The cost estimation for the solid methionine project is based on market prices and relevant cost estimation methods, ensuring its reasonableness [4][5]. - The unit construction cost for the solid methionine project is 3,593.25 yuan per square meter, which is within the range of similar projects in the region [7][12]. - The equipment costs for the projects are estimated based on supplier quotes and historical prices, ensuring that the pricing is reasonable [13][14]. Financial Justification - The financing scale is justified by the company's operational needs, cash flow, and projected funding gaps, with a future funding shortfall of approximately 5.566 billion yuan over the next three years [19].

Core Viewpoint - The document outlines the legal opinions and supplementary legal advice provided by King & Wood Mallesons regarding Blue Star Adisseo Co., Ltd.'s issuance of A-shares to specific targets, emphasizing compliance with Chinese laws and regulations [1][2][3]. Group 1: Issuance Details - The issuance includes projects such as a 150,000 tons/year solid methionine project and a 37,000 tons/year specialty feed additive project, among others [4][5]. - The company has not yet obtained the necessary overseas investment filing for the Burgos specialty feed additive project [4][5]. Group 2: Legal Compliance - The law firm confirms that it only provides opinions on Chinese legal matters and does not assess non-legal professional matters such as finance or accounting [3][4]. - The supplementary legal opinion is an integral part of the previously issued legal documents and maintains the same assumptions and premises [2][4]. Group 3: Overseas Investment - The overseas investment project is to be implemented by the company's subsidiary in Spain, focusing on specialty feed additives [7][8]. - The company has submitted the necessary overseas investment filing to the Ministry of Commerce, and there are no significant legal uncertainties expected regarding this process [10][12]. Group 4: Financial Assistance - The company has provided financial assistance to its joint venture, Calysseo, to support the construction of a facility for producing single-cell protein, which is strategically aligned with its core business [15][16]. - The financial assistance provided does not constitute a related party transaction under the Shanghai Stock Exchange rules [17][18].

北京市金杜律师事务所 关于蓝星安迪苏股份有限公司 向特定对象发行 A 股股票的补充法律意见书（一） 致：蓝星安迪苏股份有限公司 本所仅就与本次发行有关的中国法律问题发表意见，并不对有关行业、技术、 财务、会计、审计及资产评估等非法律专业事项发表意见，须重点强调的是，本 所亦不具备对前述专业事项及其相关后果进行判断的技能。本所仅根据现行有效 的中国境内法律、行政法规、部门规章和规范性文件发表意见，本所及经办律师 不具备就境外法律事项进行事实认定和发表法律意见的适当资格，并不根据任何 中国境外法律发表意见。本补充法律意见书中涉及境外法律事项的内容，均为对 发行人及其境外控股子公司出具的说明、境外律师出具的法律意见书、尽调报告 以及法律函件或说明确认的引述。就本次发行所涉及的境外法律事项，发行人聘 请了境外律师事务所等中介机构进行了调查，并由相关境外律师事务所及其他中 介机构出具了法律意见书、尽调报告、法律函件或说明确认。在本补充法律意见 书中对有关会计报表、审计报告、资产评估报告、境外律师出具的法律意见书、 尽调报告以及法律函件或说明确认等文件中某些数据和结论进行引述时，已履行 了必要的注意义务，但该等引述并不视 ...

关于蓝星安迪苏股份有限公司 向特定对象发行 A 股股票申请文件的 审核问询函的回复报告 保荐人（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 二〇二五年六月 蓝星安迪苏股份有限公司向特定对象发行 A 股股票 审核问询函回复报告 上海证券交易所： 根据贵所于 2025 年 4 月 29 日出具的《关于蓝星安迪苏股份有限公司向特定 对象发行股票申请文件的审核问询函》（上证上审（再融资）〔2025〕131 号） （以下简称"审核问询函"）的要求，蓝星安迪苏股份有限公司（以下简称"安 迪苏"、"发行人"或"公司"）已会同中信证券股份有限公司（以下简称"保 荐机构"或"保荐人"）、毕马威华振会计师事务所（特殊普通合伙）（以下简 称 "申报会计师"或"毕马威"）、北京市金杜律师事务所（以下简称"发行 人律师"、"申报律师"或"金杜"）等有关中介机构，本着勤勉尽责、诚实守 信的原则，对审核问询函所列的问题进行了逐项核查和落实，现回复如下，请予 审核。 本审核问询函回复报告的字体代表以下含义： | 审核问询函所列问题 | 黑体 | | --- | --- | | 对问题的回复 | 宋体 | 如无特别 ...